Donafenib + Envafolimab
2023KY433
Phase 2 small_molecule active
Quick answer
Donafenib + Envafolimab for Hepatocellular Carcinoma is a Phase 2 program (small_molecule) at Anhui Provincial Hospital with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Anhui Provincial Hospital
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active